Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea

References

• Redaelli A, Bell C, Casagrande J, et al. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther 2004;4:85-96
   PubMedGoogle Scholar
• De Lavallade H. Chronic myeloid leukaemia. Medicine 2013;41:275-7
   Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 2012;87:1037-45
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Malkovska V. Graft-versus-leukaemia: understanding and using the allo-immune response to treat haematological malignancies. Br J Haematol 1996;93:754-64
   PubMed Web of Science ®Google Scholar
• Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1514-36
   Web of Science ®Google Scholar
• Jabbour E, Mathisen MS, O’Brien S. 10 years of progress in chronic myelogenous leukemia. J Natl Compr Canc Netw 2012;10:1049-53
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011;117:5591-9
   PubMed Web of Science ®Google Scholar
• Litzow MR. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 2006;130:669-79
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841-51
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-203
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Mitra D, Trask PC, Iyer S, et al. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol 2012;95:263-73
   PubMed Web of Science ®Google Scholar
• Trask PC, Mitra D, Iyer S, et al. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol 2012;95:535-44
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984;63:789-99
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• O’Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009;7:984-1023
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Chronic myeloid leukaemia (CML). Australian Government Department of Human Services, 2012. Available at: http://www.medicareaustralia.gov.au/provider/pbs/drugs1/cml-glivec.jsp [Last accessed 3 October 2013]
   Google Scholar
• De Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention to treat analysis. J Clin Oncol 2008;26:3358-63
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52
   PubMed Web of Science ®Google Scholar
• Foryciarz K, Sacha T, Florek I, et al. Prognostic factors in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors – single center experience. ASH Annual Meeting Abstracts. Blood 2009;114:Abstract No. 2210
   Web of Science ®Google Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011;118:686-92
   PubMed Web of Science ®Google Scholar
• Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol 2009;89:14-23
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin 2011;27:1263-71
   PubMed Web of Science ®Google Scholar
• Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:115-21
   PubMedGoogle Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42
   PubMed Web of Science ®Google Scholar
• Kim DW, Banavali SD, Bunworasate U, et al. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 2010;34:1459-71
   PubMed Web of Science ®Google Scholar
• Access to treatments. Chronic Myelogenous Leukemia Society of Canada, 2013. Available at: http://cmlsociety.org/treatments/access/#ca-bc [Last accessed 5 October 2013]
   Google Scholar